



## MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

**Lyon, France, January 22<sup>nd</sup>, 2024 – 6:00 pm CET – [MaaT Pharma](#) (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival for patients with cancer**, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity agreement entrusted by MaaT Pharma to Kepler Cheuvreux, the following resources were listed on the liquidity account on December 31<sup>st</sup>, 2023:

- 24,236 shares
- € 34,107.60
- Number of executions on buy side on semester: 627
- Number of executions on sell side on semester: 368
- Traded volume on buy side on semester: 18,328 shares for € 122,340.49
- Traded volume on sell side on semester: 9,576 shares for € 64,693.03

As a reminder:

- the following resources appeared on the last half year statement on June 30, 2023 on the liquidity account:
  - 15,484 shares
  - € 41,285.13
- Number of executions on buy side on semester: 552
- Number of executions on sell side on semester: 431
- Traded volume on buy side on semester: 15,974 shares for € 144,745.75
- Traded volume on sell side on semester: 12,997 shares for € 122,384.16

The following resources appeared on the liquidity account when the activity started:

- 0 shares
- € 200,000.00

The liquidity contract has been in effect since March 14, 2022, in accordance with the authorization granted by the General Meeting on March 3, 2022, and renewed on June 19, 2023. The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>627</b>	<b>18,328</b>	<b>122,340.49</b>	<b>368</b>	<b>9,576</b>	<b>64,693.03</b>
03/07/2023	5	447	3,111.12	-	-	-
04/07/2023	21	845	5,391.10	-	-	-
05/07/2023	4	284	1,848.84	1	1	6.90
06/07/2023	4	111	747.03	1	1	6.84
07/07/2023	3	70	466.20	-	-	-
10/07/2023	-	-	-	1	50	335.00
12/07/2023	1	30	201.00	-	-	-
13/07/2023	3	20	133.00	-	-	-
14/07/2023	1	1	6.62	1	1	6.62
17/07/2023	3	110	715.00	-	-	-
18/07/2023	3	100	640.00	-	-	-
19/07/2023	1	20	128.00	2	40	258.40
20/07/2023	1	40	256.00	1	50	323.00
21/07/2023	1	40	256.00	-	-	-
24/07/2023	-	-	-	1	30	192.60
25/07/2023	2	21	134.40	1	1	6.40
26/07/2023	2	51	325.38	1	1	6.38
27/07/2023	1	50	320.00	4	66	423.72
28/07/2023	3	100	633.00	2	54	345.60
31/07/2023	3	100	621.00	3	71	454.40
01/08/2023	1	50	320.00	4	129	833.34
02/08/2023	2	80	508.00	-	-	-
03/08/2023	-	-	-	3	50	320.00
04/08/2023	5	31	195.30	1	1	6.30
07/08/2023	-	-	-	1	20	128.00
08/08/2023	1	20	128.00	-	-	-
09/08/2023	2	24	152.16	-	-	-
10/08/2023	1	1	6.38	1	1	6.38
11/08/2023	1	1	6.38	2	7	44.80
14/08/2023	4	50	315.00	-	-	-
15/08/2023	1	1	6.32	2	31	198.40
16/08/2023	3	31	195.30	1	1	6.38
17/08/2023	1	10	63.00	1	20	128.00
18/08/2023	2	21	132.30	1	1	6.38
21/08/2023	-	-	-	2	50	320.00
22/08/2023	2	41	258.30	1	1	6.38
23/08/2023	3	30	188.70	2	60	382.20
24/08/2023	3	30	189.00	1	20	128.00
25/08/2023	6	116	709.92	5	94	579.98
28/08/2023	5	90	547.20	2	11	69.30
29/08/2023	4	31	192.20	3	48	304.32
30/08/2023	6	370	2,353.20	-	-	-
31/08/2023	5	109	683.43	-	-	-
05/09/2023	1	1	6.30	1	1	6.30
06/09/2023	1	1	6.32	1	1	6.32
07/09/2023	7	248	1,550.00	3	150	969.00
08/09/2023	5	244	1,520.12	2	151	966.40
11/09/2023	2	6	38.04	-	-	-
12/09/2023	7	344	2,132.80	4	100	626.00
13/09/2023	2	31	195.30	5	81	515.16
14/09/2023	1	20	126.00	1	20	128.00

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>627</b>	<b>18,328</b>	<b>122,340.49</b>	<b>368</b>	<b>9,576</b>	<b>64,693.03</b>
18/09/2023	4	151	943.75	3	80	500.80
19/09/2023	5	60	369.00	2	21	130.20
20/09/2023	2	10	63.00	4	80	511.20
21/09/2023	4	100	618.00	1	50	315.00
22/09/2023	7	239	1,465.07	1	1	6.28
25/09/2023	4	110	684.20	2	50	313.00
26/09/2023	9	430	2,558.50	2	50	314.50
27/09/2023	12	791	4,445.42	5	122	744.20
28/09/2023	12	710	3,564.20	2	200	1,008.00
29/09/2023	2	50	252.00	5	300	1,554.00
02/10/2023	3	130	661.70	-	-	-
03/10/2023	18	540	2,624.40	11	400	2,000.00
04/10/2023	3	130	666.90	3	110	569.80
05/10/2023	3	234	1,404.00	18	588	3,580.92
06/10/2023	2	50	313.00	3	60	379.80
09/10/2023	9	190	1,155.20	-	-	-
10/10/2023	5	105	628.95	2	30	183.00
11/10/2023	9	167	993.65	3	49	300.37
12/10/2023	1	1	5.82	4	51	306.00
13/10/2023	6	73	427.78	2	23	140.30
16/10/2023	1	99	588.06	1	48	288.00
17/10/2023	2	11	66.00	1	1	5.98
18/10/2023	3	35	211.75	3	39	239.85
19/10/2023	6	139	849.29	3	80	498.40
20/10/2023	3	8	48.72	2	21	129.99
23/10/2023	4	67	414.73	1	20	124.00
24/10/2023	5	74	454.36	2	21	130.20
25/10/2023	2	18	111.60	1	1	6.22
26/10/2023	-	-	-	8	339	2,278.08
27/10/2023	5	140	974.40	4	49	348.88
30/10/2023	6	90	632.70	1	21	151.20
31/10/2023	2	40	286.40	12	354	2,708.10
01/11/2023	4	400	3,164.00	10	338	2,879.76
02/11/2023	19	1,720	13,553.60	-	-	-
03/11/2023	22	1,108	8,110.56	-	-	-
06/11/2023	5	77	599.83	5	82	655.18
07/11/2023	5	95	787.55	8	140	1,164.80
08/11/2023	7	125	1,028.75	1	20	166.00
09/11/2023	10	207	1,674.63	2	6	49.80
10/11/2023	20	216	1,736.64	1	1	8.06
13/11/2023	11	117	932.49	-	-	-
14/11/2023	4	69	539.58	4	48	379.68
15/11/2023	11	270	2,060.10	4	140	1,104.60
16/11/2023	5	121	917.18	4	75	574.50
17/11/2023	3	90	695.70	-	-	-
20/11/2023	10	484	3,562.24	4	61	461.16
21/11/2023	13	303	2,172.51	3	92	678.96
22/11/2023	4	63	451.71	3	43	313.90
23/11/2023	4	93	675.18	-	-	-
24/11/2023	4	65	467.35	-	-	-
27/11/2023	8	161	1,122.17	1	1	7.14

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>627</b>	<b>18,328</b>	<b>122,340.49</b>	<b>368</b>	<b>9,576</b>	<b>64,693.03</b>
28/11/2023	6	140	952.00	3	110	767.80
29/11/2023	3	200	1,380.00	1	1	6.96
30/11/2023	5	140	945.00	2	90	610.20
01/12/2023	21	389	2,594.63	13	415	3,037.80
04/12/2023	2	100	685.00	5	147	1,043.70
05/12/2023	-	-	-	2	65	455.00
06/12/2023	1	17	118.32	3	75	525.00
07/12/2023	11	349	2,348.77	3	90	618.30
08/12/2023	15	251	1,641.54	4	61	405.65
11/12/2023	7	154	1,057.98	22	1,083	7,873.41
12/12/2023	4	48	340.80	9	300	2,145.00
13/12/2023	13	238	1,635.06	-	-	-
14/12/2023	4	60	403.20	3	60	409.80
15/12/2023	9	190	1,271.10	11	300	2,055.00
18/12/2023	4	20	135.60	2	15	102.30
19/12/2023	5	71	484.22	5	21	143.43
20/12/2023	5	60	418.20	10	225	1,579.50
21/12/2023	10	92	623.76	4	81	568.62
22/12/2023	10	137	946.67	15	261	1,827.00
27/12/2023	4	75	536.25	8	210	1,507.80
28/12/2023	3	35	250.25	4	80	583.20
29/12/2023	11	314	2,179.16	8	165	1,166.55

## About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



## Contacts

### MaaT Pharma – Investor Relations

Guillaume DEBROAS, Ph.D.  
Head of Investor Relations  
+33 6 16 48 92 50  
[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

### MaaT Pharma – Media Relations

Pauline RICHAUD  
Senior PR & Corporate  
Communications Manager  
+33 6 14 06 45 92  
[media@maat-pharma.com](mailto:media@maat-pharma.com)

### Trophic Communications – Corporate Communications

Stephanie MAY or  
Priscilla PERRIN  
+49 171 351 2733  
[maat@trophic.eu](mailto:maat@trophic.eu)